VR Adviser’s Aclaris Therapeutics ACRS Stock Holding History

VR Adviser’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,040,754	Closed	-$7.13M	–	37
2023 Q3	$7.13M	Hold	1,040,754	–	–	0.75%	29
2023 Q2	$10.8M	Hold	1,040,754	–	–	1.73%	17
2023 Q1	$8.42M	Sell	1,040,754 -3,523,208	-77%	-$44.7M	1.64%	18
2022 Q4	$71.9M	Hold	4,563,962	–	–	12.11%	2
2022 Q3	$71.8M	Hold	4,563,962	–	–	11.08%	2
2022 Q2	$63.7M	Hold	4,563,962	–	–	12.55%	2
2022 Q1	$78.7M	Hold	4,563,962	–	–	12.75%	1
2021 Q4	$66.4M	Hold	4,563,962	–	–	9.07%	2
2021 Q3	$82.2M	Hold	4,563,962	–	–	10.55%	2
2021 Q2	$80.1M	Buy	4,563,962 +843,380	+23%	+$19.2M	9.72%	2
2021 Q1	$93.8M	Buy	3,720,582 +1,765,650	+90%	+$34.5M	10.17%	3
2020 Q4	$12.6M	Buy	+1,954,932	New	+$8.25M	1.86%	15

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

VR Adviser's ACRS Position: Q4 2023 in Review

VR Adviser sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 1,040,754 shares — an estimated $7.13M sold.

VR Adviser first reported a position in ACRS in Q4 2020 and held it in 12 quarters. The position peaked at $93.8M in Q1 2021. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

VR Adviser reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
VR Adviser sold 1,040,754 Aclaris Therapeutics shares in Q4 2023, an estimated $7.13M.
VR Adviser first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 12 quarters.
VR Adviser's Aclaris Therapeutics position peaked at $93.8M in Q1 2021.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on VR Adviser's 13F filing for Q4 2023, filed 14 Feb 2024.